Skip to main content
Stephanie (Schutt) Graff, MD, Oncology, Kansas City, MO

StephanieLynn(Schutt)GraffMD

Oncology Kansas City, MO

Breast Cancer, Hematologic Oncology

Physician

Dr. Graff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Graff's full profile

Already have an account?

  • Office

    2316 E Meyer Blvd
    1 Cancer West
    Kansas City, MO 64132
    Phone+1 816-276-4700
    Fax+1 816-276-3810

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
  • University of Missouri-Kansas City School of Medicine
    University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 2004 - 2007
  • University of Missouri Kansas City School of Medicine
    University of Missouri Kansas City School of MedicineClass of 2004

Certifications & Licensure

  • RI State Medical License
    RI State Medical License 2021 - 2026
  • KS State Medical License
    KS State Medical License 2008 - 2021
  • MO State Medical License
    MO State Medical License 2006 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • WhatÍs in a Name? a Gender-Based Analysis of Speaker Introductions at the American Society of Hematology Annual Meeting
    Stephanie L. Graff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • How Close Is Too Close: Navigating Difficult Situations 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Shared Decision-Making in Sequencing ADCs for HER2-Low Breast Cancer
    Shared Decision-Making in Sequencing ADCs for HER2-Low Breast CancerNovember 21st, 2024
  • New Finding “Changes the Conversation” in Metastatic Breast Cancer Care
    New Finding “Changes the Conversation” in Metastatic Breast Cancer CareOctober 22nd, 2024
  • Without New FDA Approval, How Should Adjuvant Ribociclib Be Used in Breast Cancer?
    Without New FDA Approval, How Should Adjuvant Ribociclib Be Used in Breast Cancer?August 20th, 2024
  • Join now to see all